drugset
drugset / Trial / NCT03472950

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

NCT03472950 ↗

Phase 2 Completed 14 enrolled University of Kansas Medical Center Gilead Sciences · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS). Ranolazine is an FDA approved drug that is used for decreasing chest pain.

Timeline

Start
2018-06-11
Primary completion
2020-12-11
Completion
2022-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 500 mg —
Subject Ranolazine Small molecule 1000 mg —

Indications

amyotrophic lateral sclerosis